A Study of Tacabrutideg (BGB-16673) Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors
Recruiting · Phase 3 · NCT06846671
Conditions: CLL, Chronic Lymphocytic Leukemia
At a glance
- Research payments reported, 2025
- $1,600
- U.S. investigators named
- 0
- Sites paid
- 0
- Planned or actual enrollment
- 250
About the trial
- Sponsor
- BeOne Medicines
- Tested
- Tacabrutideg (drug), Bendamustine (drug), Idelalisib (drug), Rituximab (drug), Venetoclax (drug)
- Dates
- Started 2025-04-10; completion 2030-02-14
- Results posted
- Not yet
The purpose of this study is to investigate the efficacy and safety of tacabrutideg compared with investigator's choice (idelalisib plus rituximab \[for CLL only\] or bendamustine plus rituximab or venetoclax plus rituximab retreatment) in participants with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) previously exposed to both BTK inhibitors (BTKi) and BCL2 inhibitors (BCL2i).
From ClinicalTrials.gov, last updated 2026-09-28. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Beone Medicines Ltd. reported $1,600 in research payments for this study in 2025 (1 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
Sites paid to run it
- $1,600
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.